Literature DB >> 2594947

Infections in a renal unit.

R M Higgins1.   

Abstract

Five hundred and thirty-three patients in the Oxford renal unit were reviewed to determine the incidence of infection in one calendar year. There were 310 patients who received dialysis, 53 with acute renal failure and 211 with chronic renal disease. Renal transplant patients were not included in the study. Apart from infections related to dialysis access, patients on maintenance haemodialysis or continuous ambulatory peritoneal dialysis developed few serious infections unless they had another disease causing suppression of immune function. A total of 97 urinary tract infections were seen; in patients with chronic renal disease not receiving dialysis the incidence of urinary tract infection was significantly associated with increasing uraemia, with diabetes, and with treatment with azathioprine or cyclophosphamide. In patients with acute renal failure, Gram-negative septicaemia and fungal infections were important causes of morbidity and mortality, but cardiovascular disease caused 42 per cent of the deaths unlike results from other series where sepsis has been by far the commonest cause of death.

Entities:  

Mesh:

Year:  1989        PMID: 2594947

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  3 in total

1.  Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients.

Authors:  Cécile Contin; Vincent Pitard; Yahsou Delmas; Nadège Pelletier; Thierry Defrance; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

Review 2.  Diagnosis and drug treatment of acute pyelonephritis.

Authors:  A Meyrier; J Guibert
Journal:  Drugs       Date:  1992-09       Impact factor: 9.546

Review 3.  Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review.

Authors:  Helen I McDonald; Sara L Thomas; Dorothea Nitsch
Journal:  BMJ Open       Date:  2014-04-17       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.